GleamWall
中文EN

KTTA Pasithea Therapeutics Corp.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1841330 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-84.0%
TTM EPS YoY68.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-88.8%
ROA-82.6%
ROIC (approx.)-414.6%
Asset turnover—

Leverage & solvency

Liabilities / assets5.9%
Debt / equity0.00x
Current ratio15.67x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-18.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$7.98M$7.20M
SG&A expense$12.88M$7.05M
Operating income-$20.86M-$14.25M
Pretax income-$20.43M-$13.90M
Net income-$20.43M-$13.90M
EBITDA-$20.82M-$14.23M
EPS (basic)-2.91-12.69
EPS (diluted)-2.91-12.69
Weighted avg. shares (diluted)7.03M1.10M
Balance sheet
Cash & equivalents$55.16M$6.92M
Current assets$56.46M$7.37M
PP&E, net—$122,343
Goodwill—$1.26M
Intangibles$2.90M$7.31M
Total assets$60.24M$16.06M
Current liabilities$4.97M$1.12M
Total liabilities$5.02M$1.28M
Shareholders' equity$55.22M$14.78M
Shares outstanding23.09M1.39M
Cash flow statement
Operating cash flow-$15.21M-$13.92M
Investing cash flow$11,000—
Financing cash flow$63.52M$4.52M
Depreciation & amortization$32,421$18,865
Stock-based compensation$297,467$773,693

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.